LT3001 not checked

Shanghai Pharmaceuticals Holding Co., Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Drug: LT3001 Drug:high dose Administered by intravenous infusion.”In the company’s words, NCT07754825 on ClinicalTrials.gov
Tested for
Acute Ischemic Stroke (2 trials)
Main trialPhase 2
“This phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the treatment of acute ischemic stroke”In the company’s words, NCT05686642 on ClinicalTrials.gov

Other drugs for Acute Ischemic Stroke

All 45 drugs for Acute Ischemic Stroke

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 10 Dec 2026 Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke
Phase 2Not yet recruiting 31 Dec 2027 A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow LT3001

Following is part of Solo: you see every change to LT3001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in